Brief: Biosergen AB Says First Subject Dosed In Phase I Trial Of BSG005
07/04/2022 03:49
April 6 (Reuters) - Biosergen AB BIOSGN.ST :
* FIRST VOLUNTEER HAS BEEN DOSED WITH COMPANY'S PROPRIETARY
ANTIFUNGAL DRUG CANDIDATE BSG005
Source text for Eikon: ID:nWkrbW0dqQ
Further company coverage: BIOSGN.ST
((reuters.briefs@thomsonreuters.com;))